| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
Recently, orthotopic liver transplantation is unique and the most efficient treatment for end-stage liver disease. But, the therapy has the issues of donor shortage and immune rejection. Then, a hepatocyte transplantation is listed as a alternative therapy for liver transplantation, we investigated hepatocyte transplantation.First, we selected iPS cells and mesenchymal stem cells as a cell source, and we tried and succeeded to induce differentiation of human induced pluripotent stem cells and human mesenchymal stem cells to hepatocyte like cells in vitro.In particular, the cells which was provided with extra cellular matrix and cytokines, expressed albumin and other hepatocyte marker in RT -PCR and immunohistochemistry. We transplanted these hepatocyte like cells into livers of SCID rats. In rats which were transplanted hepatocyte like cells derived from mesenchymal stem cells, we detected the albumin positive cells in the liver, in some of those rats, the serum level of human albumin increased.And then, in rats which were transplanted hepatocyte like cells derived from iPS cells, the albumin positive cells were detected in the liver .This result indicated that we can use iPS cells and mesenchymal stem cells as a cell source of hepatocyte transplantation.
|
